Skip to main content
SpringerLink
Log in

Oncology—Male Reproductive System

  • Chapter
Clinical PET and PET/CT

  • 1371 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

Testicular Cancer

  1. Albers P, Bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999; 53:808–11.

    Article  PubMed  CAS  Google Scholar 

  2. Becherer A, De Santis M, Bokemeyer C, et al. FDG-PET as prognostic indicator for seminoma residuals: an update from the SEMPET trial. J Nucl Med 2003; 5(suppl):174P.

    Google Scholar 

  3. Bokemeyer C, Kollmannsberger C, Oechsle K, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002; 86:506–11.

    Article  PubMed  CAS  Google Scholar 

  4. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998; 39:815–22.

    PubMed  CAS  Google Scholar 

  5. Cremerius U, Wildberger JE, Borchers H, et al. Dose positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999; 54:900–4.

    Article  PubMed  CAS  Google Scholar 

  6. de Geus-Oei LF, Spermon JR, Kiemeney LA, et al. Chemotherapy response monitoring with 18FDG-PET in patients with high stage testicular germ cell cancer. J Nucl Med 2003; 5(Suppl):131P.

    Google Scholar 

  7. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19:3740–4.

    PubMed  Google Scholar 

  8. Frank IN, Graham Jr SD, Nabors WL: Urologic and Male Genital Cancers, in Holleb AI, Fink DJ, Murphy GP (eds): Clinical Oncology. Atlanta, American Cancer Society, 1991.

    Google Scholar 

  9. Ganjoo KN, Chan RJ, Sharma M, et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999; 17:3457–60.

    PubMed  CAS  Google Scholar 

  10. Hain SF, O’Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumors. Eur J Nucl Med 2000; 27:590–4.

    Article  PubMed  CAS  Google Scholar 

  11. Hain SF, O’Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumors at relapse. Br J Cancer 2000; 83:863–9.

    Article  PubMed  CAS  Google Scholar 

  12. Huddart RA. Use of FDG-PET in testicular tumors. Clin Oncol (R Coll Radiol) 2003; 15:123–7.

    CAS  Google Scholar 

  13. Karapetis CS, Strickland AH, Yip D, et al. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumor following chemotherapy: single-center experience with long-term follow up. Intern Med J 2003; 33:427–35.

    Article  PubMed  CAS  Google Scholar 

  14. Lassen U, Daugaard G, Eigtved A, et al. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumors. Eur J Nucl Med Mol Imaging 2003; 396–402.

    Google Scholar 

  15. Muller-Mattheis V, Reinhardt M, Gerharz CD, et al. Positron emission tomography with [18F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe A 1998; 37:609–20.

    PubMed  CAS  Google Scholar 

  16. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumors in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997; 33:1234–41.

    Article  PubMed  CAS  Google Scholar 

  17. Pandit-Taskar N, Sinha A, Gonen M, et al. Testicular uptake in 18FDG PET scan. J Nucl Med 2003; 5(Suppl): 143P.

    Google Scholar 

  18. Reinhardt MJ, Matthies A, Biersack HJ: PET-imaging in tumors of the reproductive tract. Q J Nucl Med 2002; 46:105–12.

    PubMed  CAS  Google Scholar 

  19. Reinhardt MJ, Muller-Mattheis VG, Gerharz CD, et al. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J Nucl Med 1997; 38:99–101.

    PubMed  CAS  Google Scholar 

  20. Sanchez D, Zudaire JJ, Fernandez JM, et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumors at relapse. BJU Int 2002; 89:912–6.

    Article  PubMed  CAS  Google Scholar 

  21. Spermon JR, De Geus-Oei LF, Kiemeney LA, et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumors. BJU Int 2002; 89(6):549–56.

    Article  PubMed  CAS  Google Scholar 

  22. Tatlidil R, Jadvar H, Conti PS. Utility of FDG-PET in the evaluation of residual or recurrent testicular carcinoma: comparison to CT and serum tumor markers. Radiology 2000; 217(P):220.

    Google Scholar 

  23. Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002; 68:157–63.

    Article  PubMed  Google Scholar 

  24. Wilson CB, Young HE, Ott RJ, et al. Imaging metastatic testicular germ cell tumors with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995; 22:508–13.

    Article  PubMed  CAS  Google Scholar 

  25. Yun M, Jang S, Kim W, et al. Pattern of testicular uptake with age and the effect of chemotherapy on testicular uptake determined by FDG PET. J Nucl Med 2001; 5(Suppl): 287P.

    Google Scholar 

Prostate Cancer

  1. Chang CH, Wu HC, Tsai JJ, et al. Detecting metastatic pelvic lymph nodes by (18)f-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003; 70(4):311–315.

    Article  PubMed  Google Scholar 

  2. de Jong IJ, Pruim J, Elsinga PH, et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003; 44:331–335.

    PubMed  Google Scholar 

  3. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med 2003; 44:556–558.

    PubMed  Google Scholar 

  4. Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30:607–611.

    Article  PubMed  CAS  Google Scholar 

  5. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39(6):990–995.

    PubMed  CAS  Google Scholar 

  6. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31–35.

    Article  PubMed  CAS  Google Scholar 

  7. Jadvar H, Pinski JK, Conti PS. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep 2003; 10:1485–8.

    PubMed  Google Scholar 

  8. Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29(11):1492–1495.

    Article  PubMed  CAS  Google Scholar 

  9. Kotzerke J, Volkmer BG, Glatting G, et al. Intra-individual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42:25–30.

    PubMed  CAS  Google Scholar 

  10. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-(18)F-Fluoro-5alpha-Dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45:366–373.

    PubMed  CAS  Google Scholar 

  11. Liu IJ, Zafar MB, Lai YH, et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57:108–111.

    PubMed  CAS  Google Scholar 

  12. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913–18.

    Article  PubMed  Google Scholar 

  13. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001;22:963–969.

    Article  PubMed  CAS  Google Scholar 

  14. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4:99–104.

    PubMed  Google Scholar 

  15. Patel P, Cohade C, DeWeese T, et al. Evaluation of metabolic activity of prostate gland with PET-CT. J Nucl Med 2002; 43(5 Suppl):119P.

    Google Scholar 

  16. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucosepositron emission tomography. J Urol 2003; 169(4):1337–1340.

    PubMed  CAS  Google Scholar 

  17. Price DT, Coleman RE, Liao RP, et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273–280.

    PubMed  Google Scholar 

  18. Salminen E, Hogg A, Binns D, et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002; 41(5):425–429.

    Article  PubMed  Google Scholar 

  19. Sanz G, Robles JE, Gimenez M, et al. Positron emission tomography with 18fluorinelabelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999;84:1028–1031.

    Article  PubMed  CAS  Google Scholar 

  20. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162:1322–1328.

    PubMed  CAS  Google Scholar 

  21. Shimizu N, Masuda H, Yamanaka H, et al. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy. J Urol 1999; 161:608–609.

    PubMed  CAS  Google Scholar 

  22. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with FDG. Radiology 1996; 199:751–756.

    PubMed  CAS  Google Scholar 

  23. Shreve PD, Iannone P, Weinhold P. Cellular metabolism of [1-C14]-acetate in prostate cancer cells in vitro. J Nucl Med 2002; 43(5 Suppl):272P.

    Google Scholar 

  24. Sung J, Espiritu JI, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 2003; 92:24–7.

    Article  PubMed  CAS  Google Scholar 

  25. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgenindependent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23:693–697.

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2005). Oncology—Male Reproductive System. In: Clinical PET and PET/CT. Springer, London. https://doi.org/10.1007/1-84628-100-8_11

Download citation

  • DOI: https://doi.org/10.1007/1-84628-100-8_11

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-838-1

  • Online ISBN: 978-1-84628-100-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation